Rheumatoid Arthritis Clinical Trial
— MAJIKOfficial title:
JAKINIB Study: " 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA."
NCT number | NCT04602091 |
Other study ID # | MAJIK Registry |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 8, 2019 |
Est. completion date | June 2030 |
Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real life further established. The French Society of Rheumatologists intends to coordinate a prospective national registry study for this follow-up. This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for 5 years. This registry is a longitudinal, multicentre, observational registry study. The objective of this national registry is to get a better understanding of the safety profiles of JAK inhibitors and get knowledge of their use in daily practice in order to optimize this use and potentially integrate JAK inhibitors into personalised medicine strategies. This registry will generate efficacy data, especially therapeutic maintenance, observation, allowing inter-registry comparisons with other biologic compounds in the French population, and can be aggregated with other similar registries in other countries.
Status | Recruiting |
Enrollment | 2300 |
Est. completion date | June 2030 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria - Patients older than 18 - Patient treated with a JAK inhibitor in accordance with EMA, for chronic inflammatory rheumatisms, independent of the therapeutic line - Subject who is a member of a social security regime - Free, declared, written consent signed by the subject and the investigator on the day of inclusion Exclusion criteria - Patient who cannot understand the implications and rules of the study - Patient opposition to participating in the study |
Country | Name | City | State |
---|---|---|---|
France | CH Antibes | Antibes | |
France | Private office | Bayonne | |
France | CH Franche Comte | Belfort | |
France | CHU de Besançon | Besançon | |
France | AP-HP Avicenne | Bobigny | |
France | CHU de Bordeaux | Bordeaux | |
France | CH Bourg-en-Bresse | Bourg-en-Bresse | |
France | CHRU Brest | Brest | |
France | CHU Caen | Caen | |
France | CH Cannes | Cannes | |
France | CH Chartres | Chartres | |
France | CH Cholet | Cholet | |
France | CHU Clermont Ferrand | Clermont-Ferrand | |
France | CH Colombes | Colombes | |
France | AP-HP Henri Mondor | Créteil | |
France | CH Dax | Dax | |
France | CH de Dijon | Dijon | |
France | CH de Douai | Douai | |
France | CHD de Vendee | La Roche-sur-Yon | |
France | CH La Rochelle | La Rochelle | |
France | CHG Jacques Monod | Le Havre | |
France | AP-HP Bicetre | Le Kremlin-Bicêtre | |
France | CH Le Mans | Le Mans | |
France | CHU Lille | Lille | |
France | Private office | Limoges | |
France | CH Saint Philibert | Lomme | |
France | CHU Lyon | Lyon | |
France | Infirmerie protestante de Lyon | Lyon | |
France | CHU Marseille Sainte-Marguerite | Marseille | |
France | Hôpital Saint Joseph | Marseille | |
France | CH Mont de Marsan | Mont-de-Marsan | |
France | CHU de Montpellier | Montpellier | |
France | CH Morlaix | Morlaix | |
France | GH de Mulhouse | Mulhouse | |
France | CHU Nantes | Nantes | |
France | CH Nevers | Nevers | |
France | CHU Nice | Nice | |
France | CH Niort | Niort | |
France | CH Orleans | Orléans | |
France | AP-HP Ambroise Pare | Paris | |
France | AP-HP Bichat | Paris | |
France | AP-HP Lariboisiere | Paris | |
France | AP-HP Pitie-Salpetriere | Paris | |
France | AP-HP Saint Antoine | Paris | |
France | Hôpital Cochin | Paris | |
France | Hopital La Croix Saint Simon | Paris | |
France | CH Pau | Pau | |
France | CHU Reims | Reims | |
France | CHU Rouen | Rouen | |
France | CHU de la Reunion | Saint-Denis | |
France | CHU Saint Etienne | Saint-Étienne | |
France | CH Bégin | Saint-Mandé | |
France | CH Saint Nazaire | Saint-Nazaire | |
France | CHU Strasbourg | Strasbourg | |
France | CHU Toulouse | Toulouse | |
France | CHU Tours | Tours | |
France | CH Troyes | Troyes | |
France | CH Valence | Valence | |
France | CH Valenciennes | Valenciennes | |
France | Polyclinique Vauban | Valenciennes |
Lead Sponsor | Collaborator |
---|---|
Societe Francaise de Rhumatologie | Bordeaux PharmacoEpi |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Therapeutic maintenance of JAK inhibitors | The therapeutic maintenance will be measured by the retention rate ie the percentage of patients remaining treated by JAK inhibitors. | From the beginning of the study up to Year 1 | |
Secondary | Real-life tolerance of JAK inhibitors | Occurence of adverse events and action taken (temporary or final stop to JAK inhibitor treatment upon the occurrence of adverse event). | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Real-life tolerance of JAK inhibitors in sub-groups | Occurence of adverse events and action taken (temporary or final stop to JAK inhibitor treatment upon the occurrence of adverse event), in an older population or presenting with comorbidities | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Efficacy of JAK inhibitors | Evaluated using clinical data (list is not exhaustive): number of swelling joints (NAG), number of tender joints (NAD), erythrocyte sedimentation rate (ESR), levels of C-reactive protein (CRP), the visual analogic scale (VAS) for disease activity evaluated by the patient and by the physician. | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Comparison of JAK inhibitors efficacy (monotherapy versus combination with DMARDS) | Evaluate the efficacy of JAK inhibitors administered as monotherapy versus combination with a conventional synthetic DMARDs | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Efficacy of JAK inhibitors dose (full doses versus half doses) | From the beginning of the study until the end of the 5 years follow-up | ||
Secondary | Use of JAK inhibitors in current practice | Starting dosage, therapeutic adjustments, etc. | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Place of JAK inhibitors in real-life practice in the treatment arsenal for patients with chronic inflammatory rheumatic disorders | Therapeutic history of the patient regarding DMARDs before starting treatment with a JAK inhibitor | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Patient reported outcomes: Quality of life | Analyse the effect of JAK inhibitors on patient reported outcomes in regard to quality of life and functional impact : Health Assessment Questionnaire (HAQ) questionnaire | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Patient reported outcomes: Acceptance | Analyse the effect of JAK inhibitors on patient reported outcomes in regard to acceptance : treatment acceptance questionnaire | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Patient reported outcomes: Compliance | Analyse the effect of JAK inhibitors on patient reported outcomes in regard to Compliance : compliance questionnaire (Morisky-Green self-questionnaire) | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Drug interactions | Identify new drug interactions | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Analysis if data from a National Health Database (SNIIRAM): demographics | With and without chaining to the patients included in this cohort with the possibility of evaluating demographics | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Analysis if data from a National Health Database (SNIIRAM): medical economics | With and without chaining to the patients included in this cohort with the possibility of evaluating medical economics | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Analysis if data from a National Health Database (SNIIRAM): compliance | With and without chaining to the patients included in this cohort with the possibility of evaluating compliance | From the beginning of the study until the end of the 5 years follow-up | |
Secondary | Establishment of an open database | Establish an open database which can be integrated with other national registries with a view toward future international analyses | From the beginning of the study until the end of the 5 years follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |